inactive HBsAg carrier
Conditions
Interventions
A:pegIFN alfa 2a 135ug/week or combine with adefovir 10mg/day, for 96weeks
B:no antiviral therapy
Sponsors
Beijing You’an Hosipital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: HBsAg positive >6months and HBsAg<1000IU/ml,HBeAg negative, anti-HBe postive, anti-HBc positive. HBV DNA<2000IU/ml. ALT normal. treatment naive for antiviral therapy
Exclusion criteria
Exclusion criteria: 1) cirrhosis; 2) diagnosed or suspected hepatocellular carcinoma(HCC); 3) allergy to IFN or nucleoside; 4) acute or chronic liver disease due to HAV,HCV,HDV or HEV infetion; 5) alcohol or drug abuse; 6) auto-immune liver disease, malignant carcinoma, IFN contraindication (e.g. Severe heart disease, Renal failure, uncontroled asthma, uncontroled diabetes mellitus, Autoimmune thyroiditis or other active autoimmune disorders, Uncontrolled seizures, Present or past psychosis or severe depression, presence of treatment for active pulmonary tuberculosis, psoriasis), pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAg clerance rate at week 96; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBsAg seroconversion rate at week 96;HBV DNA undetactable rate at week 96; | — |
Countries
China
Contacts
Public ContactXinyue Chen
Outcome results
None listed